Oncolytics Biotech Inc.
HealthcareNASDAQ:ONCY · NASDAQ Capital Market
-$0.02 today
Vol 0.65M · Avg 1.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
757.0%
avg 3773.9%
ROIC
-1716.0%
avg -269.1%
ROA
-379.3%
avg -120.0%
Analysis
ROE is currently the strongest return metric at 757.0% versus its period average of 3773.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas C. Heineman | Chief Medical Officer | $675,471.00 | — | 67 | $0.00 | <0.01% |
Jared Kelly | Chief Executive Officer & Director | $582,150.00 | — | 40 | $114,050.00 | 0.11% |
Kirk J. Look | Chief Financial Officer | $575,183.00 | — | 54 | $287,515.00 | 0.29% |
Allison Hagerman | Chief Technology Officer | $350,354.00 | — | 42 | $115,059.00 | 0.11% |
John Mark Lievonen | Consultant | $18,609.00 | — | — | $0.00 | <0.01% |
Jon Patton | Director of Investor Relations & Communication | — | — | — | — | — |
Andrew Aromando | Chief Business Officer | — | — | 56 | $55,100.00 | 0.05% |
John McAdory | Chief Operating Officer | — | — | 49 | $0.00 | <0.01% |
Yujun Wu | VP & Head of Biostatistics | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$362,615.06
Sells
0
$0.00
Net Sentiment
+$362,615.06
Net buying
Most Active
Kelly Jared
3 transactions
1–10 of 14
Analysis
Insiders reported 14 buys worth $362,615.06 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $362,615.06. Kelly Jared was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Surrozen, Inc.
NASDAQ:SRZN
$174.90M
Coya Therapeutics, Inc.
NASDAQ:COYA
$86.31M
Clene Inc.
NASDAQ:CLNN
$60.20M
Instil Bio, Inc.
NASDAQ:TIL
$53.71M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
Who manages ONCY?
Oncolytics Biotech Inc. (ONCY) lists 9 active executives. The top listed executive is Thomas C. Heineman, Chief Medical Officer.
Are ONCY insiders buying or selling?
Recent insider activity shows net buying of $362,615.06.
Explore More
Continue the stock analysis
Jump to another research area for this company.